Emerging treatments

Panobinostat in combination with bortezomib and dexamethasone as induction therapy in patients with multiple myeloma candidates to autologous transplant. Mangiacavalli S et al. Leuk Lymphoma. 2014 Oct 27:1-8. [Epub ahead of print]. Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide. Lau IJ…

Biology and genetics

Immune impairments in multiple myeloma bone marrow mesenchymal stromal cells. André T et al. Cancer Immunol Immunother. 2014 Oct 24. [Epub ahead of print]. Inhibition of Akt-signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy. van der Waart AB et al. Blood. 2014 Oct 21. pii: blood-2014-05-578583. [Epub ahead of print]. Global…

Supportive care

Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience. Cerchione C et al. Support Care Cancer. 2014 Oct 24. [Epub ahead of print]. Bisphosphonates do not delay engraftment after autologous SCT in patients with newly diagnosed myeloma. Oksman MJ et al. Bone Marrow Transplant. 2014 Oct…

General

Haematological cancer: Optimizing the treatment of multiple myeloma. Morgan GJ et al. Nat Rev Clin Oncol. 2014 Oct 28. doi: 10.1038/nrclinonc.2014.185. [Epub ahead of print]. The Role of Bendamustine in the Management of Plasma Cell Myeloma. Gertz MA. Leuk Lymphoma. 2014 Oct 27:1-5. [Epub ahead of print]. Non-hodgkin lymphoma risk and insecticide, fungicide and fumigant…

Complications of myeloma and its treatments

Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Blimark C et al. Haematologica. 2014 Oct 24. pii: haematol.2014.107714. [Epub ahead of print]. Drug-Induced Modulation of T Lymphocytes as a Potential Mechanism of Susceptibility to Infections in Patients with Multiple Myeloma During Bortezomib Therapy. Li J et al. Cell Biochem Biophys. 2014…

Current treatments

Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma. Tuchman SA et al. J Clin Apher. 2014 Oct 8. doi: 10.1002/jca.21360. [Epub ahead of print]. Improved response rates with bortezomib in relapsed or refractory multiple myeloma: an observational study in chinese patients. Lin M et al. Adv Ther. 2014…

Diagnostic tests and prognostic indicators

Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method. Manasanch EE et al. Leuk Lymphoma. 2014 Sep 27:1-24. [Epub ahead of print]. Protein Expression for Novel Prognostic Markers (Cyclins D1, D2, D3, B1, B2, ITGβ7, FGFR3, PAX5) Correlate With Previously…

Related conditions

Finger amyloidosis in a patient with myeloma. Tan J et al. Intern Med. 2014;53(18):2175-6. Epub 2014 Sep 15. Bone marrow findings of the newly described TEMPI syndrome: when erythrocytosis and plasma cell dyscrasia coexist. Rosado FG et al. Mod Pathol. 2014 Sep 12. doi: 10.1038/modpathol.2014.117. [Epub ahead of print]. Systemic amyloidosis causing intestinal hemorrhage and…

Emerging treatments

Phase I Trial of Bortezomib and “Non-Hybrid “(Bolus) Infusion Schedule of Alvocidib (Flavopiridol) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms. Holkova B et al. Clin Cancer Res. 2014 Sep 23. pii: clincanres.0805.2014. [Epub ahead of print]. Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review. He X et al.…

Biology and genetics

Deazaneplanocin A Is a Promising Drug to Kill Multiple Myeloma Cells in Their Niche. Gaudichon J et al. PLoS One. 2014 Sep 25;9(9):e107009. doi: 10.1371/journal.pone.0107009. eCollection 2014. HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment. Borsi E et al. Exp Cell Res. 2014 Sep 25. pii: S0014-4827(14)00423-6. doi: 10.1016/j.yexcr.2014.09.018.…